AML Patho Physiology & Classification - V Roccha
Transcript of AML Patho Physiology & Classification - V Roccha
![Page 1: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/1.jpg)
Acute Myeloid Leukemia
Marcelo C Pasquini, MD, MSAssistant Professor of Medical College of Wisconsin, Milwaukee, USA
Vanderson Rocha, MD, PhDMedical Assistant of HSCT unit, Hopital Saint Louis, Paris, FranceChair of the Acute Leukemia Working Party of EBMTVisiting Professor of Medical College of Wisconsin, Milwaukee, USA
![Page 2: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/2.jpg)
OutlineOutline
Acute Myeloid Leukemia: overview
Classification
General aspects of AML treatment
HVD05_2.ppt
![Page 3: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/3.jpg)
Epidemiology: AML
• 10,500 New Cases in USA 2001• Incidence is stable for the last 3
decades• Median age: 63 years (70 y in Sweden) • Most common acute leukemia in adults• Sharp increase in incidence after the
6th decade of life.
![Page 4: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/4.jpg)
Hematopoiesis Scheme
Stem CellCompartment
LymphoidCompartment
MyeloidCompartment
![Page 5: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/5.jpg)
![Page 6: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/6.jpg)
Details of the Myeloid Compartment
![Page 7: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/7.jpg)
Marrow DisordersMarrow Disorders
-normal+/-Differentiation
+/-+/-+++Apoptosis
++++++Proliferation
Acute Leukemia
MPDMDS
MDS: Myelodysplasia; MPD: Myeloproliferative Disorder
![Page 8: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/8.jpg)
NormalHematopoiesis Leukemogenesis
![Page 9: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/9.jpg)
Acute Myeloid LeukemiaAcute Myeloid Leukemia
• Two major distinctions: – Secondary AML
• (MDS or therapy related);
– “de novo” AML .
• FAB classification (morphological)– M0, M1, M2, M3, M4, M5, M6, M7
• WHO classification (“risk adapted”)
MNC03_11.ppt
![Page 10: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/10.jpg)
Secondary AMLSecondary AML
• AML that arises from myelodysplasia and/or secondary to previous chemotherapy:
– Multilineage dysplasia
– Poor risk cytogenetic findings
– Poor response to therapy
– Incidence increases with age
– Poor response to therapy
– Lower survival compared to “de novo” AML
MNC03_12.ppt
![Page 11: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/11.jpg)
• Lack of significant multilineagedysplasia;
• Good risk cytogenetics t(8;21), t(15;17), inv 16 or t(16;16);
• Favorable response to therapy;
MNC03_13.ppt
““De novoDe novo”” AMLAML
![Page 12: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/12.jpg)
FAB ClassificationFAB Classification
![Page 13: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/13.jpg)
AML and Morphologic Differences
![Page 14: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/14.jpg)
Cytogenetic Changes and AML Cytogenetic Changes and AML OutcomesOutcomes
![Page 15: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/15.jpg)
Region 2
Region 1
Region 1
Region 2
Region 3
4321321123
21
1234
Short arm 'p'
Centromere
Long arm 'q'
![Page 16: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/16.jpg)
Normal Male Karyotype: 46, XY
![Page 17: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/17.jpg)
47, XY, +8
![Page 18: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/18.jpg)
Chromosomal abnormalities
Structural abnormalities- Translocation- Deletion- Inversion
Numerical changes- Hyperdiploidy 50- 65 chromosomes.
- Trisomie- Near haploidy 26-34 chromosomes,
- Monosomie
![Page 19: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/19.jpg)
Report SampleReport Sample
![Page 20: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/20.jpg)
Region 2
Region 1
Region 1
Region 2
Region 3
4321321123
21
1234
Short arm 'p'
Centromere
Long arm 'q'
![Page 21: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/21.jpg)
Chromosomal Morphologic AssociationAbnormality FAB- AML
Trisomy 8 VariableMonosomy 7 M2,M4,M5Monosomy 5, de(5q) M1,M2t(8;21)(q22;q22) M2,*M4t(15;17)(q22;q11-12) M3t(9;11)(p22;q23) M5,M4,M2del(11)(q22 –23) M5,M4,M2inv(16)(p13;q22), del(16q) M4Eo,M2,M5t(6;9)(p13;q34) M1,M2,M4; t(9;22)(q34;q11) M1
![Page 22: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/22.jpg)
FAB ClassificationFAB Classification
![Page 23: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/23.jpg)
AML M0AML M0
CD13+,CD33+.MPO<3%
![Page 24: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/24.jpg)
AML M1AML M1
MPO +
CD13+,CD33+,CD117+,CD65s+.
MPO
![Page 25: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/25.jpg)
AML M2AML M2
MPO +CD13+,CD33+,CD117+,CD65s+CD19+,CD56+.
t(8;21)(q22;q22) AML1 / ETO
![Page 26: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/26.jpg)
M2M2
![Page 27: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/27.jpg)
M3M3
![Page 28: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/28.jpg)
M4eoM4eo
![Page 29: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/29.jpg)
AML M5 aAML M5 a
CD34+,CD33+,CD117+,CD14+CD34+,CD33+,CD117+,CD14+
t(9;11)(p21;q23)t(9;11)(p21;q23)
AF9 / MLLAF9 / MLL
![Page 30: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/30.jpg)
Acute Acute ErythremiaErythremia
GlyGly A+A+
t(9;22)(q34;q11)t(9;22)(q34;q11)
ABL / BCR
![Page 31: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/31.jpg)
AML M7AML M7
CD34+,CD117+.CD34+,CD117+.
CD41a+,CD61+.CD41a+,CD61+.
![Page 32: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/32.jpg)
How about FISH?How about FISH?
FFlorescence lorescence IIn n SSitu itu HHybridizationybridization
![Page 33: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/33.jpg)
Cytogenetic EvaluationCytogenetic Evaluation
NoYesCell culture
YesNoAbnormality specific
Metaphase and Interphase
MetaphaseCell cycle
200-50020Cells analyzed
FISHStd Cytog.
![Page 34: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/34.jpg)
![Page 35: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/35.jpg)
Overall Survival by SWOG Cytogenetic Risk Status
Slovak et al, Blood 2000; 96: 4075-4083
![Page 36: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/36.jpg)
Overall Survival by MRC “Good” Cytogenetic RiskCompared to Intermediate Risk
Grimwade et al, Blood 1998; 92: 2322-2333
![Page 37: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/37.jpg)
![Page 38: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/38.jpg)
WHO AMLClassification
![Page 39: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/39.jpg)
AML WHO CLASSIFICATIONAML WHO CLASSIFICATION
• Recognizes three sub groups
–AML with recurrent genetic abnormalities
–AML with multilineage dysplasia• Includes secondary AML (MDS, therapy
related)
–AML not otherwise categorized
MNC03_15.ppt
![Page 40: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/40.jpg)
• AML with recurrent genetic abnormalities
–AML with t(8;21)
–AML with t(16;16) or inv 16
–APML or AML with t(15;17)
–AML with 11q23 abnormalities
• Favorable response to therapy
MNC03_16.ppt
AML WHO CLASSIFICATIONAML WHO CLASSIFICATION
![Page 41: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/41.jpg)
• AML with multilineage dysplasia
– Following MDS
– Without antecedent MDS, but with dysplasia in at least 50% of cells in 2 or more myeloid lineage
– Therapy related MDS or AML• Alkylating agent, irradiation-related,
topoisomerase II inhibitor
MNC03_17.ppt
AML WHO CLASSIFICATIONAML WHO CLASSIFICATION
![Page 42: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/42.jpg)
• AML, not otherwise categorized
• Defined almost identically as in the FAB classification
• Based on identification of major cell lineage(s) involved and degree of maturation
MNC03_18.ppt
AML WHO CLASSIFICATIONAML WHO CLASSIFICATION
![Page 43: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/43.jpg)
AML with normal cytogenetics
• New Good–NPM1 mutation without FLT3 ITD–CEBPA mutation
• New Bad–FLT3 ITD–MLL PTD–KIT mutation (t(8;21))–Overexpression of BALLC
![Page 44: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/44.jpg)
![Page 45: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/45.jpg)
Risk Stratification with Molecular Markers
• More complex to tease out.• Combination of different
abnormalities• Location of a mutation• Development of molecular
signatures (microarray)
![Page 46: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/46.jpg)
Additional Risk Factors for Poor Outcome
• Age• WBC at diagnosis, blasts in bone
marrow.• Platelet count• Remission duration
![Page 47: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/47.jpg)
Initial AML TreatmentInitial AML Treatment
InductionInduction PostPost--Remission TherapyRemission Therapy
CR
Allogeneic BMTAllogeneic BMT
ConsolidationConsolidationChemotherapyChemotherapy
Autologous BMTAutologous BMT
DiagnosisDiagnosisDiagnosis
Primary Induction Failure
CR: Complete Remission
![Page 48: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/48.jpg)
Cassileth et al, NEJM 1998; 339: 1649-56
AML OS by Different Treatment Strategies:US Intergroup
![Page 49: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/49.jpg)
![Page 50: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/50.jpg)
Definitions of Response and RelapseDefinitions of Response and Relapse
• Important milestones that predict future outcomes
• Complete remission: no evidence of disease
• Levels of relapse/remission:–Hematological (Increase blasts in the
BM, blood, extramedullary disease)–Cytogenetics [t(15;17); t(8;21)]–Molecular (PML/RARα, RUNX/MTG8)
![Page 51: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/51.jpg)
Active DiseaseActive Disease
HematologicHematologic
CytogeneticCytogenetic
MolecularMolecular
Treatment
Dis
ease
Bu
rden
Dis
ease
Bu
rden
CML Model
![Page 52: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/52.jpg)
![Page 53: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/53.jpg)
AML Salvage treatment
• Mylotarg (gemtuzomab ozogomycin)• Decitabine• Auto HCT• Allogeneic HCT• Other investigational agents: p-
glycoprotein inhibitor (vorinostat), FLT3 inhibitors, temozolamide, tipafarnib.
![Page 54: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/54.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
%
Early (N=3,174)
0 2 61 3
Years
4 5
SUM06_16.ppt
Probability of Survival after HLA-identical Sibling Donor Transplants for AML with Myeloablative Conditioning, 1998-2004
- by Disease Status -
P < 0.001
Intermediate (N=785)
Advanced (N=1,278)
Slide 24
![Page 55: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/55.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
%
Early (N=1,063)
0 2 61 3
Years
4 5
SUM06_17.ppt
Probability of Survival after Unrelated Donor Transplants with Myeloablative
Conditioning for AML, 1998-2004- by Disease Status -
P < 0.001
Intermediate (N=1,066)
Advanced (N=1,251)
Slide 25
![Page 56: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/56.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
% Early (N=804)
0 2 61 3
Years
4 5
SUM06_18.ppt
Probability of Survival after HLA-identical Sibling Transplants with Myeloablative
Conditioning for AML, Age <20 Years, 1998-2004- by Disease Status -
P < 0.001
Intermediate (N=174)
Advanced (N=165)
Slide 26
![Page 57: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/57.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
%
Early (N=2,369)
0 2 61 3
Years
4 5
SUM06_19.ppt
Probability of Survival after HLA-identical Sibling Transplants with Myeloablative
Conditioning for AML, Age ³20 Years, 1998-2004- by Disease Status -
P < 0.001
Intermediate (N=611)
Advanced (N=1,113)
Slide 27
![Page 58: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/58.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
%
Early (N=428)
0 2 61 3
Years
4 5
SUM06_20.ppt
Probability of Survival after HLA-identical Sibling Transplants with Reduced Intensity
Conditioning for AML, 1998-2004- by Disease Status -
P < 0.001
Intermediate (N=164)
Advanced (N=232)
Slide 28
![Page 59: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/59.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
%
Early (N=249)
0 2 61 3
Years
4 5
SUM06_21.ppt
Probability of Survival after Unrelated Donor Transplants with Reduced Intensity
Conditioning for AML, 1998-2004- by Disease Status -
P < 0.001
Intermediate (N=184)
Advanced (N=260)
Slide 29
![Page 60: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/60.jpg)
0
20
40
60
80
100
Pro
bab
ilit
y,
%
Early, RIC (N=278)
0 2 61 3
Years
4 5
SUM06_22.ppt
Probability of Survival after HLA-identical Sibling Transplants for AML, Age >50 Years, 1998-2004
- by Disease Status and Conditioning Regimen Intensity -
P = 0.54
Intermediate, Myeloablative (N=133)
Intermediate, RIC (N=113)
Early, Myeloablative (N=467)
Slide 30
RIC = Reduced Intensity Conditioning
![Page 61: AML Patho Physiology & Classification - V Roccha](https://reader030.fdocuments.net/reader030/viewer/2022020217/546c3bcdb4af9fae2c8b489e/html5/thumbnails/61.jpg)
Thanks for your attention